Abstract:Background Advanced stage PBC is characterized by immune response, portal inflammation and liver fibrosis, and can be attributed to enhanced atypical ductular reaction (DR) and biliary senescence. Dominant‐negative transforming growth factor beta receptor II (dnTGFβRII) mice phenotypically mimic some features of late stage PBC at 34 wks of age. MCs infiltrate the liver of humans and murine models of cholestasis, and reside adjacent to bile ducts. Activated MCs release large amounts of tryptase, as well as histamine (HA) that that can act through its specific receptors, H1‐H4 HRs on bile ducts. In models of cholestasis, we have found that blocking MC activation and HR signaling reduces biliary senescence and liver fibrosis. However, the role of MCs and HA signaling during PBC are unknown. The aim of our study was to determine changes in MC and HA signaling during advanced stage PBC, and the therapeutic potential of blocking MCs in our model of advanced stage PBC. Methods Female human control and advanced stage PBC samples were analyzed for: (i) MC presence by immunostaining for tryptase and MC‐specific markers by q PCR, (ii) H2HR expression by IHC and q PCR, and (iii) tryptase serum levels by EIA. H2HR expression was evaluated in senescent bile ducts by co‐staining. For in vivo studies we utilized female (i) wild‐type (WT), (ii) dnTGFβRII and (iii) dnTGFβRII treated with cromolyn sodium (24 mg/kg/BW) for 1 wk by intraperitoneally implanted osmotic minipump mice at 34 wks of age. MC presence was determined by staining for chymase and tryptase. MC activation was determined by serum tryptase and HA levels by EIA. H2HR expression was evaluated by immunostaining. Liver damage was evaluated by H&E, and serum levels of ALP and AMA. Atypical DR was visualized by CK‐19 staining and correlated with liver inflammation shown by F4/80 staining. Biliary senescence was determined by q PCR and staining for SA‐β‐Galactosidase, p18 and IL‐1β. Liver fibrosis and hepatic stellate cell activation was assessed by Sirius Red staining and quantification, desmin staining and serum TGF‐β1 levels by EIA. Results Human advanced stage PBC samples showed enhanced hepatic MC number and activation, and activated MCs were found near senescent bile ducts. There was increased hepatic H2 HR expression, which was was upregulated in senescent bile ducts in human advanced stage PBC. dnTGFβRII mice at 34 wks of age had increased MC number/activation, H2HR expression, atypical DR, inflammation, biliary senescence and liver fibrosis; however, all of these parameters were reduced in dnTGFβRII mice treated with cromolyn sodium. Conclusion Increased MC activation and biliary H2HR expression may drive PBC progression through enhanced biliary senescence that promotes liver fibrosis in a paracrine manner. Inhibition of MC activation via cromolyn sodium treatment may be a therapeutic option for advanced stage PBC patients. Support or Funding Information NIH NIDDK R01s, VA Merit, Indiana University School of Medicine

Mast Cell (MC) Activation and Histamine (HA) Signaling Promotes Atypical Ductular Reaction, Biliary Senescence and Liver Fibrosis During Advanced Stage Primary Biliary Cholangitis (PBC)

Mast cells selectively target large cholangiocytes during biliary injury via H2HR‐mediated cAMP/pERK1/2 signaling

Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Human Placental Mesenchymal Stem Cells Relieve Primary Sclerosing Cholangitis via Upregulation of TGR5 in Mdr2-/- Mice and Human Intrahepatic Cholangiocyte Organoid Models

P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases

Dominant-Negative Mice Receptor II b Biliary Cirrhosis in TGF-Anti-Mitochondrial Antibodies and Primary

Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis

Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice.

The Critical Role of Th1 Cytokine Polarization in Murine Primary Biliary Cirrhosis. (P4154)

High-fat diet modulates bile acid composition and gut microbiota, affecting severe cholangitis and cirrhotic change in murine primary biliary cholangitis

Regulatory T Cells with a Defect in Inhibition on Co-Stimulation Deteriorated Primary Biliary Cholangitis

Effect of Allogeneic Bone Marrow–derived Mesenchymal Stem Cells Transplantation in a Polyi:C-Induced Primary Biliary Cirrhosis Mouse Model

Dysregulation of Peritoneal Cavity B1a Cells and Murine Primary Biliary Cholangitis

Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation

Invariant NKT cells exacerbate liver injury in a TGF-beta receptor II dominant-negative mouse model of primary biliary cirrhosis

The HSP90 inhibitor 17‐DMAG alleviates primary biliary cholangitis via cholangiocyte necroptosis prevention

Natural Killer T Cells Exacerbate Liver Injury In A Transforming Growth Factor Beta Receptor Ii Dominant-Negative Mouse Model Of Primary Biliary Cirrhosis

The critical role of Th1 cytokine polarization in murine primary biliary cirrhosis